血清CA19—9、CA125、CA242、CEA联检诊断胰腺癌的临床价值

目的：评价血清糖类抗原19—9（CA19—9），糖类抗原125（CA125），糖类抗原242（CA242）及癌胚抗原（CEA）四项指标联检对胰腺癌的诊断价值。方法：四项标志物均应用全自动化学免疫分析检测。结果：胰腺癌患者血清CA19—9、CA125、CA242、CEA水平明显高于胰腺良性病组，差异均有显著性（P〈0．01）。四项指标联检诊断胰腺癌的敏感性为91．7％，特异性92．1％。结论：血清CA19—9、CA125、CA242及CEA单项检测在胰腺癌诊断中特异性均偏低，且四项联检可提高胰腺癌的敏感性及特异性，临床诊断价值更大。

Diagnostic Value of Combined Detection of Serum CA 19-9, CA 125, CA 242 and CEA in Patients with Pancreatic Cancer

Objective To study the diagnostic value of combined detection of four tumor markers (carbohydrate antigen 19-9, carbohydrate antigen 125, carbohydrate antigen 242, carcinoembryonic antigen) in patients with pancreatic cancer. Methods Serum levels of these four markers were measured with full-automatic chemiluminescence immune assay in 36 patients with pancreatic cancer and 38 patients with benign pancreatic disorders. Results The serum levels of CA19-9, CA125, CA242 and CEA in patients with pancreatic cancer were significantly higher than those in patients with benign pancreatic diseases (P<0.01). With combined detection of CA19-9, CA125, CA242 and CEA in patients with pancreatic cancer, the sensitivity and specificity was 91.7% and 92.1% respectively. Conclusion While the diagnostic sensitivily and specificity for pancreatic cancer with any single marker were clinically not satisfactory, combined determination of CA19-9, CA125, CA242 and CEA could greatly improve the diagnostic accuracy.